NCT02593539View on ClinicalTrials.gov

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

July 22, 2016

Primary Completion Date

June 4, 2020

Study Completion Date

June 4, 2020

Conditions

Activated PI3K-delta Syndrome

Interventions

DRUG

Nemiralisib

Participants will be administered nemiralisib

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT02593539 - Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI | Biotech Hunter | Biotech Hunter